The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Adjuvants for cancer vaccines
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Adaptive Immunity by the Innate Immune System
Iwasaki, A., & Medzhitov, R. (2010) · Science · doi:10.1126/science.1183021 · Cited by 2,157
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Self-citationPathogen recognition in the innate immune response
Kumar, H., Kawai, T., & Akira, S. (2009) · Biochemical Journal · doi:10.1042/bj20090272 · Cited by 590
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists
Vollmer, J., & Krieg, A. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.12.008 · Cited by 585
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Self-citationHeat shock proteins and immune system
Tsan, M.-F., & Gao, B. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0109005 · Cited by 471
Stils, H. F. (2005) · ILAR Journal · doi:10.1093/ilar.46.3.280 · Cited by 434
The path to a successful vaccine adjuvant – ‘The long and winding road’
O’Hagan, D. T., & De Gregorio, E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.009 · Cited by 274
Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S., Tavarini, S., Sammicheli, C., Hilbert, A. K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813390106 · Cited by 261
Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., & Persing, D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1129 · Cited by 256
Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
(How) do aluminium adjuvants work?
BREWER, J. (2006) · Immunology Letters · doi:10.1016/j.imlet.2005.08.002 · Cited by 236
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J., Daphtary, M. M., Biedrzycki, B., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236
Sun, H.-X., Xie, Y., & Ye, Y.-P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.032 · Cited by 235
Mechanism of action of licensed vaccine adjuvants
Tritto, E., Mosca, F., & De Gregorio, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.084 · Cited by 213
Zhu, Q., Egelston, C., Vivekanandhan, A., Uematsu, S., Akira, S., Klinman, D. M., Belyakov, I. M., & Berzofsky, J. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805325105 · Cited by 183
The cancer vaccine roller coaster
Goldman, B., & DeFrancesco, L. (2009) · Nature Biotechnology · doi:10.1038/nbt0209-129 · Cited by 174
Ott, G., Barchfeld, G. L., & Nest, G. V. (1995) · Vaccine · doi:10.1016/0264-410x(95)00089-j · Cited by 147
Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer
Jasani, B., Navabi, H., & Adams, M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.071 · Cited by 146
Saul, A. J., Lawrence, G., Smillie, A., Rzepczyk, C. M., Reed, C., Taylor, D. F., Anderson, K., Stowers, A. W., Kemp, R. J., Allworth, A. M., et al. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00175-9 · Cited by 140
Developing an HPV vaccine to prevent cervical cancer and genital warts
Bryan, J. T. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.013 · Cited by 123
Baldwin, S. L., Shaverdian, N., Goto, Y., Duthie, M. S., Raman, V. S., Evers, T., Mompoint, F., Vedvick, T. S., Bertholet, S., Coler, R. N., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.081 · Cited by 101
Self-citationThe PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
Heimberger, A. B., & Sampson, J. H. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903124346 · Cited by 94
Gilewski, T. A., Ragupathi, G., Dickler, M. N., Powell, S., Bhuta, S., Panageas, K., Koganty, R. R., Chin-Eng, J., Hudis, C. A., Norton, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2189 · Cited by 91
Emulsion-based adjuvants for influenza vaccines
Vogel, F. R., Caillet, C., Kusters, I. C., & Haensler, J. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.5 · Cited by 88
Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®
Schwarz, T. F. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0079-5 · Cited by 83
Adjuvants for Pandemic Influenza Vaccines
Atmar, R. L., & Keitel, W. A. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-92165-3_16 · Cited by 69
Brichard, V. G., & Lejeune, D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.951 · Cited by 62
Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
Palena, C., & Schlom, J. (2010) · BioMed Research International · doi:10.1155/2010/380697 · Cited by 58
Clinical and Immunologic Basis of Interferon Therapy in Melanoma
Tarhini, A. A., & Kirkwood, J. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05073.x · Cited by 47
Baras, B., Cam, N. L., Devaster, J., Fries, L. F., Gillard, P. H., Sänger, R., & Hanon, E. (2008) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2008.00054.x · Cited by 42
Antibody Inducing Polyvalent Cancer Vaccines
Ragupathi, G., Gathuru, J., & Livingston, P. O. (2005) · Cancer treatment and research · doi:10.1007/0-387-27545-2_7 · Cited by 41
Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W., Ingolia, D. E., Mayo, M., Denney, D. W., & Levy, R. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802563355 · Cited by 40
Cited by
Lv, M., Chen, M., Zhang, R., Zhang, W., Wang, C., Zhang, Y., Wei, X., Guan, Y., Liu, J., Feng, K., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00395-4 · Cited by 1,040
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Self-citationcGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
Metadata
- Authors
- Dubensky, T. W., & Reed, S. G.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 22
- Issue
- 3
- Pages
- 155-161
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2061178426
- Cited by
- 259
- References
- 37
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.